New real-world evidence from ASH 2025: How anti-BCMA therapies are sequenced in relapsed/refractory multiple myeloma
During the Amercain Society of Hematology (ASH) meeting and exposition 2025, a major international...
Two new real-world posters from ISPOR Europe 2025: Severe Asthma and Resectable NSCLC
At ISPOR Europe 2025, APLUSA shared two real-world evidence posters focused on high-impact...
Delivering market research in niche regions where data is scarce
In today’s rapidly evolving healthcare landscape, having timely and reliable market insights is...
Case Study: Tracking the Evolution of CAR-T and Immunotherapy Practices in DLBCL
In this case study, we explore how APLUSA’s global research framework delivered data-driven clarity...
Beyond Data: The People and Purpose Powering APLUSA
At APLUSA, our strength lies in our people, their expertise, collaboration, and shared passion for...
Understanding ALK+ NSCLC caregivers’ psychosociological burden: insights from ESMO 2025
A collaborative poster by APLUSA and Takeda, presented at the European Society for Medical Oncology...
APLUSA Stats App is Back Online!
At APLUSA, we know that in the pharmaceutical industry, every number matters. Whether you are...
Obesity in France: Evolving Care Pathways, Innovations, and Market Perspectives
Obesity has become a major public health issue in France. It currently affects more than 8 million...
Multiple Myeloma: The Dawn of a New Era in Treatment
Recent years have brought transformative breakthroughs for people battling multiple myeloma....
Social Media Impact of the 66th ASH Annual Meeting & Exposition 2024
Digital, hemato-oncology, Social Media Listening, Oncology
The ASH Annual Meeting & Exposition 2024 took place from December 7th to 10th, 2024, in San Diego,...